Tuya Announces Director Appointment
As of the date of this press release, the Board comprises Mr. Wang Xueji, Mr. Chen Liaohan, Mr.
"We welcome our current vice president of finance,
The Board also warmly welcomes
About Tuya Inc.
Tuya Inc. (NYSE: TUYA; HKEX: 2391) is a global leading cloud platform service provider with a mission to build a smart solutions developer ecosystem and enable everything to be smart. Tuya has pioneered a purpose-built cloud developer platform with cloud and generative AI capabilities that delivers a full suite of offerings, including Platform-as-a-Service, or PaaS, Software-as-a-Service, or SaaS, and smart solutions for developers of smart device, commercial applications, and industries. Through its cloud developer platform, Tuya has activated a vibrant global developer community of brands, OEMs, AI agents, system integrators and independent software vendors to collectively strive for smart solutions ecosystem embodying the principles of green and low-carbon, security, high efficiency, agility, and openness. For more information, please visit https://ir.tuya.com/overview/default.aspx
Disclosure Information
Tuya uses the https://ir.tuya.com/overview/default.aspx website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the
Investor Relations Contact
Tuya Inc.
Investor Relations
Email: [email protected]
The Blueshirt Group
Phone: +1 (323) 240-5796
Email: [email protected]
View original content:https://www.prnewswire.com/news-releases/tuya-announces-director-appointment-302308870.html
SOURCE Tuya Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Energy Vault acquires Goshe Energy Storage, adding 2.3 GW of BESS projects
- Lantern Pharma receives USPTO patent allowance for LP-284 through 2042
- Vertex reports Phase 2b kidney disease drug data, enrolls Phase 2/3 trial
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share